{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:24:34Z","timestamp":1778862274342,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["81670154\/H0812,81470355\/H1616 and 81100378\/H0812"],"award-info":[{"award-number":["81670154\/H0812,81470355\/H1616 and 81100378\/H0812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["81272451\/H1609, 81472762\/H1609"],"award-info":[{"award-number":["81272451\/H1609, 81472762\/H1609"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Foundation of Guangzhou Science and Technology Innovation Committee, Bureau of Education of Guangzhou Municipality, GD-NSF and Guangdong special support scheme","award":["201707010352, 1201410214, 2014A030313492, 201528042"],"award-info":[{"award-number":["201707010352, 1201410214, 2014A030313492, 201528042"]}]},{"name":"National Funds for developing local colleges and universities","award":["B16056001"],"award-info":[{"award-number":["B16056001"]}]},{"name":"GD-NSF for research team","award":["2018B030312001"],"award-info":[{"award-number":["2018B030312001"]}]},{"name":"MOE","award":["20134423110002"],"award-info":[{"award-number":["20134423110002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The first line therapy for patients with diffuse large B cell (DLBCL) is R-CHOP. About half of DLBCL patients are either refractory to, or will relapse, after the treatment. Therefore, identifying novel drug targets and effective therapeutic agents is urgently needed for improving DLBCL patient survival. b-AP15, a selective small molecule inhibitor of proteasomal USP14 and UCHL5 deubiquitinases (DUBs), has shown selectivity and efficacy in several other types of cancer cells. This is the first study to report the effect of b-AP15 in DLBCL.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cell lines of two DLBCL subtypes, Germinal Center B Cell\/ GCB (SU-DHL-4, OCI-LY-1, OCI-LY-19) and Activated B Cell\/ABC (SU-DHL-2), were used in the current study. Cell viability was measured by MTS assay, proliferation by trypan blue exclusion staining assay, cellular apoptosis by Annexin V-FITC\/PI staining and mitochondrial outer membrane permeability assays, the activities of 20S proteasome peptidases by cleavage of specific fluorogenic substrates, and cell migration was detected by transwell assay in these GCB- and ABC-DLBCL cell lines. Mouse xenograft models of SU-DHL-4 and SU-DHL-2 cells were used to determine in vivo effects of b-AP15 in DLBCL tumors.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>b-AP15 inhibited proteasome DUB activities and activated cell death pathway, as evident by caspase activation and mitochondria apoptosis in GCB- and ABC- DLBCL cell lines. b-AP15 treatment suppressed migration of GCB- and ABC-DLBCL cells via inhibiting Wnt\/\u03b2-catenin and TGF\u03b2\/Smad pathways. Additionally, b-AP15 significantly inhibited the growth of GCB- and ABC DLBCL in xenograft models.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results indicate that b-AP15 inhibits cell migration and induces apoptosis in GCB- and ABC-DLBCL cells, and suggest that inhibition of 19S proteasomal DUB should be a novel strategy for DLBCL treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-019-1446-y","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T15:03:40Z","timestamp":1573052620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma"],"prefix":"10.1186","volume":"38","author":[{"given":"Liling","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuening","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q. Ping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"1446_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","volume":"14","author":"R Camicia","year":"2015","unstructured":"Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.","journal-title":"Mol Cancer"},{"issue":"2","key":"1446_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.semdp.2011.04.001","volume":"28","author":"C Schneider","year":"2011","unstructured":"Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol. 2011;28(2):167\u201377.","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"1446_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146\u201371.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1446_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2007.1.265","volume":"2007","author":"Margaret A. Shipp","year":"2007","unstructured":"Shipp MA. Molecular signatures define new rational treatment targets in large B-cell lymphomas. Hematology Am Soc Hematol Educ Program 2007, ASH Education Book. 2007;2007(1):265\u20139","journal-title":"Hematology"},{"issue":"36","key":"1446_CR5","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1446_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","volume":"165","author":"J Iqbal","year":"2004","unstructured":"Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, Dave S, Xiao L, Cao K, Zhu Q, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159\u201366.","journal-title":"Am J Pathol"},{"issue":"13","key":"1446_CR7","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2013-06-508028","volume":"122","author":"H Nogai","year":"2013","unstructured":"Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, et al. IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. Blood. 2013;122(13):2242\u201350.","journal-title":"Blood"},{"issue":"1","key":"1446_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1 Suppl 2","key":"1446_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/sonc.2002.30153","volume":"29","author":"B Coiffier","year":"2002","unstructured":"Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002;29(1 Suppl 2):30\u20135.","journal-title":"Semin Oncol"},{"issue":"15","key":"1446_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417\u201329.","journal-title":"N Engl J Med"},{"issue":"18","key":"1446_CR11","first-page":"3111","volume":"125","author":"JS Abramson","year":"2019","unstructured":"Abramson JS. Hitting back at lymphoma: how do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment? Cancer-Am Cancer Soc. 2019;125(18):3111\u201320.","journal-title":"Cancer-Am Cancer Soc"},{"issue":"5","key":"1446_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","volume":"8","author":"D Chauhan","year":"2005","unstructured":"Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8(5):407\u201319.","journal-title":"Cancer Cell"},{"issue":"8","key":"1446_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","volume":"130","author":"JL Harousseau","year":"2017","unstructured":"Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130(8):963\u201373.","journal-title":"Blood"},{"issue":"4","key":"1446_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10555-016-9640-2","volume":"35","author":"Z Xiao","year":"2016","unstructured":"Xiao Z, Zhang P, Ma L. The role of deubiquitinases in breast cancer. Cancer Metastasis Rev. 2016;35(4):589\u2013600.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1446_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10555-017-9701-1","volume":"36","author":"X Chen","year":"2017","unstructured":"Chen X, Yang Q, Xiao L, Tang D, Dou QP, Liu J. Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents. Cancer Metastasis Rev. 2017;36(4):655\u201368.","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"1446_CR16","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.biocel.2012.07.011","volume":"44","author":"P D'Arcy","year":"2012","unstructured":"D'Arcy P, Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol. 2012;44(11):1729\u201338.","journal-title":"Int J Biochem Cell Biol"},{"key":"1446_CR17","first-page":"32","volume":"147","author":"P D'Arcy","year":"2015","unstructured":"D'Arcy P, Wang X, Linder S. Deubiquitinase inhibition as a cancer therapeutic strategy. PharmacolTher. 2015;147:32\u201354.","journal-title":"PharmacolTher"},{"issue":"3","key":"1446_CR18","first-page":"539","volume":"15","author":"S Shinji","year":"2006","unstructured":"Shinji S, Naito Z, Ishiwata S, Ishiwata T, Tanaka N, Furukawa K, Suzuki H, Seya T, Matsuda A, Katsuta M, et al. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol Rep. 2006;15(3):539\u201343.","journal-title":"Oncol Rep"},{"issue":"9","key":"1446_CR19","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1074\/jbc.M808507200","volume":"284","author":"MA Mines","year":"2009","unstructured":"Mines MA, Goodwin JS, Limbird LE, Cui FF, Fan GH. Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK ativation. J Biol Chem. 2009;284(9):5742\u201352.","journal-title":"J Biol Chem"},{"issue":"54","key":"1446_CR20","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.1038\/sj.onc.1208944","volume":"24","author":"SJ Wicks","year":"2005","unstructured":"Wicks SJ, Haros K, Maillard M, Song L, Cohen RE, Dijke PT, Chantry A. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene. 2005;24(54):8080\u20134.","journal-title":"Oncogene"},{"issue":"9","key":"1446_CR21","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1007\/s10620-012-2181-9","volume":"57","author":"Y Chen","year":"2012","unstructured":"Chen Y, Fu D, Xi J, Ji Z, Liu T, Ma Y, Zhao Y, Dong L, Wang Q, Shen X. Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig Dis Sci. 2012;57(9):2310\u20137.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"1446_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ejh.12784","volume":"98","author":"M Delforoush","year":"2017","unstructured":"Delforoush M, Berglund M, Edqvist PH, Sundstrom C, Gullbo J, Enblad G. Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma. Eur J Haematol. 2017;98(1):52\u20136.","journal-title":"Eur J Haematol"},{"issue":"12","key":"1446_CR23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/nm.2536","volume":"17","author":"P D'Arcy","year":"2011","unstructured":"D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17(12):1636\u201340.","journal-title":"Nat Med"},{"issue":"5","key":"1446_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014;123(5):706\u201316.","journal-title":"Blood"},{"issue":"3","key":"1446_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bjh.13304","volume":"169","author":"K Chitta","year":"2015","unstructured":"Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, et al. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstrommacroglobulinaemiatumour cells. Br J Haematol. 2015;169(3):377\u201390.","journal-title":"Br J Haematol"},{"issue":"5","key":"1446_CR26","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","volume":"15","author":"X Shi","year":"2009","unstructured":"Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009;15(5):1686\u201397.","journal-title":"Clin Cancer Res"},{"key":"1446_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-genet-102108-134850","volume":"43","author":"C Wang","year":"2009","unstructured":"Wang C, Youle RJ. The role of mitochondria in apoptosis*. Annu Rev Genet. 2009;43:95\u2013118.","journal-title":"Annu Rev Genet"},{"key":"1446_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.biopha.2018.07.171","volume":"107","author":"C Ruiduo","year":"2018","unstructured":"Ruiduo C, Ying D, Qiwei W. CXCL9 promotes the progression of diffuse large B-cell lymphoma through up-regulating beta-catenin. Biomed Pharmacother. 2018;107:689\u201395.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"1446_CR29","doi-asserted-by":"publisher","first-page":"15098","DOI":"10.1002\/jcb.28772","volume":"120","author":"Q Li","year":"2019","unstructured":"Li Q, Liu X, Zhao C. Smad4 gene silencing enhances the chemosensitivity of human lymphoma cells to adriamycin via inhibition of the activation of transforming growth factor beta signaling pathway. J Cell Biochem. 2019;120(9):15098\u2013105.","journal-title":"J Cell Biochem"},{"key":"1446_CR30","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1038\/oncsis.2013.28","volume":"2","author":"H Jung","year":"2013","unstructured":"Jung H, Kim BG, Han WH, Lee JH, Cho JY, Park WS, Maurice MM, Han JK, Lee MJ, Finley D, et al. Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling. ONCOGENESIS. 2013;2:e64.","journal-title":"ONCOGENESIS"},{"issue":"Pt 5","key":"1446_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1042\/BST0340761","volume":"34","author":"SJ Wicks","year":"2006","unstructured":"Wicks SJ, Grocott T, Haros K, Maillard M, Ten DP, Chantry A. Reversible ubiquitination regulates the Smad\/TGF-beta signalling pathway. Biochem Soc Trans. 2006;34(Pt 5):761\u20133.","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"1446_CR32","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1158\/0008-5472.CAN-06-3254","volume":"67","author":"SJ Strauss","year":"2007","unstructured":"Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007;67(6):2783\u201390.","journal-title":"Cancer Res"},{"issue":"1","key":"1446_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1871529X11313010003","volume":"13","author":"O Fuchs","year":"2013","unstructured":"Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc HematolDisord Drug Targets. 2013;13(1):16\u201334.","journal-title":"Cardiovasc HematolDisord Drug Targets"},{"issue":"24","key":"1446_CR34","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","volume":"113","author":"K Dunleavy","year":"2009","unstructured":"Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069\u201376.","journal-title":"Blood"},{"issue":"38","key":"1446_CR35","doi-asserted-by":"publisher","first-page":"63232","DOI":"10.18632\/oncotarget.18774","volume":"8","author":"J Cai","year":"2017","unstructured":"Cai J, Xia X, Liao Y, Liu N, Guo Z, Chen J, Yang L, Long H, Yang Q, Zhang X, et al. A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. Oncotarget. 2017;8(38):63232\u201346.","journal-title":"Oncotarget"},{"issue":"1","key":"1446_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4161\/auto.3424","volume":"3","author":"E Corcelle","year":"2007","unstructured":"Corcelle E, Djerbi N, Mari M, Nebout M, Fiorini C, Fenichel P, Hofman P, Poujeol P, Mograbi B. Control of the autophagy maturation step by the MAPK ERK and p38: lessons from environmental carcinogens. Autophagy. 2007;3(1):57\u20139.","journal-title":"Autophagy"},{"issue":"4","key":"1446_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/1759-7714.12453","volume":"8","author":"B Zhang","year":"2017","unstructured":"Zhang B, Li M, Huang P, Guan XY, Zhu YH. Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma. Thorac Cancer. 2017;8(4):344\u20139.","journal-title":"Thorac Cancer"},{"issue":"11","key":"1446_CR38","doi-asserted-by":"publisher","first-page":"11427","DOI":"10.1007\/s13277-014-2446-3","volume":"35","author":"L Wang","year":"2014","unstructured":"Wang L, Chen YJ, Xu K, Wang YY, Shen XZ, Tu RQ. High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer. Tumour Biol. 2014;35(11):11427\u201333.","journal-title":"Tumour Biol"},{"key":"1446_CR39","doi-asserted-by":"publisher","first-page":"33116","DOI":"10.1038\/srep33116","volume":"6","author":"L Nan","year":"2016","unstructured":"Nan L, Jacko AM, Tan J, Wang D, Zhao J, Kass DJ, Ma H, Zhao Y. Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFbeta-1 signaling by de-ubiquitinating and stabilizing Smad2\/Smad3 in pulmonary fibrosis. Sci Rep. 2016;6:33116.","journal-title":"Sci Rep"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1446-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:47:17Z","timestamp":1604537237000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1446-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"22 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study has been examined by the Ethics Committee of the Guangzhou Medical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}